Vivos Therapeutics Reports Q2 Loss, Going Concern Warning, and High-Cost Financing
VVOS sits 25% above its 52-week low of $0.271.
Summary
Vivos Therapeutics' Q2 2026 10-Q shows a $5.5M loss, $1.8M cash, a going concern warning, and new high-interest loans. The Streeterville debt exchange terms are now quantified, adding dilution and lender control.
Updates
· GlobeNewswire — Q2 revenue rose 35% to $5.2 million with gross margin of 57%; operating loss was $4.9 million.
Key Events · Earnings and Guidance · VVOS
-
Q2 Net Loss and Cash Burn
Net loss of $5.5 million for Q2 2026, with cash down to $1.8 million as of June 30, 2026. Management reiterates substantial doubt about the company's ability to continue as a going concern.
-
High-Cost Short-Term Loans
Subsequent to quarter end, Vivos entered into two loans totaling $1.05 million (gross) at a combined effective interest rate of approximately 38%, maturing April 2027.
-
Streeterville Debt Exchange Quantified
The previously announced debt exchange is now triggered: $3.2 million of senior debt converts into 1,812,031 common shares at $0.4139 per share and 2,500 shares of Series B Non-Convertible Preferred Stock at $1,000 per share. The preferred stock carries a 9% dividend and requires Streeterville consent for future financings over $2.5 million.
-
CFO Transition
Bradford Amman resigned as CFO effective July 31, 2026. Roman Franklin was appointed CFO through a managed services agreement with The CFO Portal, LLC.
Analysis · VVOS · Industrial Applications And Services
A $5.5 million net loss for Q2 2026, with only $1.8 million in cash and a reiterated going concern warning, underscores the precarious financial position. The company also disclosed two short-term loans at a combined 38% effective interest rate and a CFO change. The debt exchange with Streeterville is now quantified: $3.2 million of debt converts into 1.8 million common shares at $0.4139 and 2,500 preferred shares, adding significant dilution and restrictive covenants. This filing confirms the high cost of survival financing.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VVOS was trading at $0.34 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.8M. The 52-week trading range was $0.27 to $5.12. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.